Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Kidney Disease: full-pipeline trial registry
32 of 103 indexed Chronic Kidney Disease trials are currently recruiting.
Corpus placement: #130 of 28,707 conditions by registered trial count.
103 US clinical trials · 32 currently recruiting · #130 of 28,707 conditions by registered trial count
Chronic Kidney Disease: 103 US clinical trials tracked, 32 recruiting.
Chronic Kidney Disease is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 8 of these trials.
Enrollment posture brief
Registry condition chronic-kidney-disease
OPEN 32 | RECR 31% | LATE 27 | EARLY 27 | RANK #130 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Eosinophilic Esophagitis (31% recruiting · 45 trials)
Chronic Kidney Disease lists 32 open slots (31% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Kidney Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Kidney Disease is recruiting below its size-band peers.
32 of 103 indexed trials (31.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Kidney Disease trials is spread across many organizations.
Bayer accounts for 8 of 103 trials (7.8%). 68 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Kidney Disease enrolment sits around 124 participants.
Median target enrolment is 124 among the 102 trials that report a genuine target (sentinel values excluded). 43 of those (42.2%) plan for fewer than 100 participants.
-
Chronic Kidney Disease research is mostly interventional.
82 interventional and 21 observational studies make up this index (79.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
103 total, page 1 of 3
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Bayer
NCT06278207
The KidneyCARE (Community Access to Research Equity) Study
Tufts Medical Center
NCT05497518
Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake
Scaled Insights
NCT06533254
A Natural History Study of Metabolic Sizing in Health and Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05398783
Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
University of Michigan
NCT01016613
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Johns Hopkins Bloomberg School of Public Health
NCT00327860
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
Northwestern University
NCT01644903
Sickle Cell Kidney Biorepository
University of Texas Southwestern Medical Center
NCT07064174
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Novo Nordisk A/S
NCT06717698
University of Michigan "Nephrology Research BioBank"
University of Michigan
NCT00381121
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Boehringer Ingelheim
NCT06926660
Transforming Hemodialysis-Related Vascular Access Education
University of Pennsylvania
NCT05997875
Empagliflozin Treatment in Kidney Transplant Recipients
VA Office of Research and Development
NCT06013865
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Bayer
NCT05196035
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
University of Chicago
NCT06397456
Patient-driven Management of BP in CKD
VA Office of Research and Development
NCT05546099
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Emory University
NCT05928936
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
University of Alabama at Birmingham
NCT06173323
Pivotal Study of the Velocity™ pAVF System
Venova Medical
NCT07153939
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
AstraZeneca
NCT07024823
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Boehringer Ingelheim
NCT07107945
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
Novartis Pharmaceuticals
NCT07235059
Sympatholysis in Chronic Kidney Disease
Emory University
NCT02411773
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Bayer
NCT05457283
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
University of Colorado, Denver
NCT06860711
The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease
Brigham and Women's Hospital
NCT07222683
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
University of Mississippi Medical Center
NCT07052539
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Amgen
NCT03633708
Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
Mayo Clinic
NCT06306963
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
NYU Langone Health
NCT05981183
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
Cedars-Sinai Medical Center
NCT06877169
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
The University of Texas at Arlington
NCT03982160
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
Bayer
NCT06608212
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Novo Nordisk A/S
NCT05021835
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Bayer
NCT05348733
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company
NCT05803421
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Alexion Pharmaceuticals
NCT05746559
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
Bayer
NCT06522997
Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans
VA Office of Research and Development
NCT04064086
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
NCT05536804
Cancer and Blood Pressure Management, CARISMA Study
ECOG-ACRIN Cancer Research Group
NCT04467021
Dine and DASH Into Wellness Pilot Study
Duke University
NCT07175896
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
Novo Nordisk A/S
NCT06122961
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Boehringer Ingelheim
NCT03594110
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00064753
Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)
Arbor Research Collaborative for Health
NCT02440659
A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)
University of Minnesota
NCT01290614
Dialysis Clinical Outcomes Revisited (DCOR) Trial
Genzyme, a Sanofi Company
NCT00324571
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Bayer
NCT05254002
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
Affymax
NCT00597753
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 17 |
| Phase 3 | 19 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Kidney Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Kidney Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Kidney Disease page
103 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 32 Chronic Kidney Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bayer sponsors the most Chronic Kidney Disease trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Kidney Disease condition card totals 103 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.